β -catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer

Conclusion: ß-catenin activation, coupled with K-ras mutation and p53 loss, activates an autocrine PDGF/Src signaling in pancreatic cancer and defines a subset of patients who might be sensitive to Src inhibition. In addition, serum PDGF level could be a reliable biomarker for patient selection in clinic.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research